Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer
Open Access
- 1 June 1999
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 10 (6) , 731-733
- https://doi.org/10.1023/a:1008303921033
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialismAnnals of Oncology, 1998
- Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancerAnnals of Oncology, 1998
- Challenges associated with evaluating the clinical utility of non-cytotoxic pharmaceutical agents in oncologyZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- A call for change in anticancer drug evaluationEuropean Journal Of Cancer, 1997